NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

On September 18, 2023 NuCana plc (NASDAQ: NCNA) reported four presentations at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) 2023 being held October 11-15, 2023 in Boston, Massachusetts (Press release, Nucana BioPharmaceuticals, SEP 18, 2023, View Source [SID1234635209]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of NuCana’s presentations at the meeting are as follows:

Abstract title: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)
Poster number: B048
Session: Poster Session B
Session date and time: Friday, October 13 from 12:30pm-4:00pm
Presenting Author: Dr. Khurum Khan

Abstract title: Phase II study of NUC-3373, leucovorin, irinotecan (NUFIRI) + bevacizumab vs FOLFIRI + bevacizumab for the second-line treatment of patients with advanced/metastatic colorectal cancer (NuTide:323)
Poster number: B049
Session: Poster Session B
Date and time: Friday, October 13 from 12:30pm-4:00pm
Presenting Author: Professor Richard Wilson

Abstract title: Phase Ib/II open label, multi-arm, parallel cohort dose finding and expansion study of NUC-3373 in combination with pembrolizumab in patients with advanced solid tumors or docetaxel in patients with lung cancer (NuTide:303)
Poster number: C029
Session: Poster Session C
Session date and time: Saturday, October 14 from 12:30pm-4:00pm
Presenting Author: Professor Richard Wilson

Abstract title: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 study
Poster number: C032
Session: Poster Session C
Session date and time: Saturday, October 14 from 12:30pm-4:00pm
Presenting Author: Professor Sarah Blagden